Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02349828
Other study ID # NEU-SIUSM-15-001
Secondary ID
Status Withdrawn
Phase Phase 2/Phase 3
First received January 23, 2015
Last updated April 19, 2016
Start date September 2015
Est. completion date April 2016

Study information

Verified date April 2016
Source Southern Illinois University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

A prospective, randomized trial to calculate incidence of Herpes Simplex Virus in an in-patient burn population and determine efficacy of prophylactic antiviral therapy to prevent viral infection and/or reactivation. Hypothesis is that antiviral prophylaxis will be effective in reducing HSV infection/reactivation.


Description:

A prospective, randomized trial of antiviral prophylaxis of at risk individuals has yet to be performed. We anticipate that the disease burden in our population of burn patients will be large, especially in patients who exhibit high risk characteristics, and hypothesize that antiviral prophylaxis will significantly reduce the incidence of Herpes Simplex Virus in the burn population. This study will have a profound impact on the treatment of burn patients both at our own institution and throughout the country. Prophylactic treatment using Acyclovir in burn patients would decrease patient morbidity, pain and suffering and would likely positively impact scarring, wound healing, and, ultimately, patient satisfaction and quality of life. Reducing the incidence of HSV infections will decrease the length of hospital stays for many patients, saving both health care expenses and resources. If prophylactic Acyclovir becomes standard of care treatment for burn patients, this treatment plan would be a tremendous public health breakthrough for preventing HSV outbreaks and could be extrapolated to researching similar protocols for other health conditions.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 24 Months and older
Eligibility Inclusion Criteria:

- Patients presenting to Memorial Medical Center's Regional Burn Unit, both transfers and direct admissions

- Patients aged 24 months to 110 years old

- Patients presenting with thermal, flame, flash, chemical, grease or electrical burns

- Patients with second degree or higher burn to the face or burn to any part of the body of 20% TBSA or greater

- Patients, power of attorney or legally authorized representative cognitively competent to give consent.

Exclusion Criteria:

- Patients who do not wish to consent to all facets of the study

- Patients younger than 24 months

- Patients older than 110 years of age

- Patients with mechanical skin injury (ie, road rash, crush injury)

- Patients who are pregnant or become pregnant during the treatment phase of the study

- Patients with a documented allergy to Acyclovir, Famcyclovir or Valacyclovir

- Patients already taking Acyclovir, Famcyclovir or Valacyclovir

- Patients who have or develop thrombotic thrombocytopenic purpura

- Patients have or develop hemolytic uremic syndrome

- Patients concurrently taking Tizanidine, Phenytoin, Valproic Acid, Fosphenytoin, Meperidine, Micophenolic Acid, Tenofovir Disoproxil Fumarate, or Zidovudine

- Patients whom the investigator feels would be inappropriate.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Acyclovir


Locations

Country Name City State
United States Southern Illinois University School of Medicine Springfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
Southern Illinois University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of Herpes Simplex Virus Herpes Simplex Virus 1 2 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT05468619 - Neonatal Phase 1 Valacyclovir Study Phase 1
Recruiting NCT01176409 - Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Phase 3
Completed NCT04664127 - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Completed NCT00448227 - Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Phase 2
Completed NCT00000139 - Herpetic Eye Disease Study (HEDS) II Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT02209324 - Open-label Study of ASP2151 in Herpes Simplex Patients Phase 3
Completed NCT00855309 - Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia Phase 3
Completed NCT01602562 - Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients Phase 3
Completed NCT00973466 - Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients N/A
Completed NCT00698893 - Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults Phase 1
Active, not recruiting NCT05298254 - A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes Phase 1/Phase 2
Recruiting NCT03178747 - Tzanck Smear With Methylene Blue Stain for Herpes Phase 3
Completed NCT00164424 - Episodic Acyclovir Therapy for Genital Ulcers Phase 2/Phase 3
Completed NCT00161434 - A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons Phase 4
Terminated NCT04762511 - A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years Phase 1
Completed NCT00699764 - Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease Phase 3
Recruiting NCT04065971 - Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. Phase 4
Active, not recruiting NCT00005663 - A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Phase 3
Recruiting NCT00006132 - Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System Phase 3